HPV vaccine shows promise for japanese men in landmark trial
NCT ID NCT04635423
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tested the 9-valent HPV vaccine (Gardasil 9) in over 1,000 Japanese males aged 16 to 26. The goal was to see if the vaccine could prevent persistent HPV infections that can lead to genital warts and anal cancers. Participants received either the vaccine or a placebo, and the study tracked infections and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
9-valent HPV vaccine (Gardasil 9)
What this could lead to
If successful, this could confirm that the 9vHPV vaccine effectively prevents HPV infections and related diseases in Japanese males, supporting its use in this population.
What could go wrong
The trial is completed, but results may not apply to all males or other populations. Some participants may experience injection-site reactions or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WARTS, GENITAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 6424)
Kawasaki, Kanagawa, 210-0852, Japan
-
Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 6404)
Tokyo, 101-0041, Japan
-
Iwasa Clinic ( Site 6411)
Osaka, 542-0073, Japan
-
Kanno Clinic ( Site 6402)
Sakai, Osaka, 590-0024, Japan
-
Kusunoki Clinic ( Site 6412)
Tokyo, 175-0092, Japan
-
Medical Corporation Iseikai My City Clinic ( Site 6414)
Tokyo, 160-0022, Japan
-
Medical Corporation Mori to Umi Tokyo Tokyo Kamata Hospital ( Site 6418)
Tokyo, 144-0051, Japan
-
Medical Corporation Sanshikai Toru Clinic ( Site 6401)
Tokyo, 132-0011, Japan
-
Medical Corporation Seiwakai Hayakawa Clinic ( Site 6409)
Osaka, 542-0086, Japan
-
Mildix Skin Clinic ( Site 6423)
Tokyo, 120-0034, Japan
-
Naoko Dermatology Clinic ( Site 6417)
Tokyo, 158-0097, Japan
-
Nomura Clinic Namba ( Site 6405)
Osaka, 542-0076, Japan
-
Ocean Clinic ( Site 6407)
Yokohama, Kanagawa, 231-8331, Japan
-
Ogikuboekimae Clinic ( Site 6413)
Tokyo, 167-0051, Japan
-
P-One Clinic, Keikokai Medical Corp. ( Site 6419)
Hachiōji, Tokyo, 192-0071, Japan
-
Seiyukai Medical Corporation Itoh Skin Clinic ( Site 6416)
Tokyo, 154-0024, Japan
-
Shinjuku Higashiguchi Clinic ( Site 6415)
Tokyo, 160-0022, Japan
-
Sugisawa Dermatology Clinic ( Site 6422)
Tokyo, 125-0041, Japan
-
Taisei Clinic ( Site 6403)
Tokyo, 107-0052, Japan
-
Umeyama Clinic ( Site 6406)
Takasaki, Gunma, 370-0826, Japan
-
Yamanaka Clinic ( Site 6410)
Osaka, 553-0001, Japan
-
Yuge Clinic ( Site 6421)
Tokyo, 103-0014, Japan